康芝药业：暂停苏拉明钠临床入组

证券之星10-31

证券之星消息，康芝药业(300086)10月30日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘你好，康大和美国合作公司的苏拉明钠治疗肾损伤的临床进展如何了

康芝药业回复：尊敬的投资者，您好！公司关于苏拉明钠对利尿剂抵抗的急性肾损伤适应症研究，鉴于有临床试验显示苏拉明钠在对利尿剂抵抗的急性肾损伤适应症上未观察到统计学显著获益。基于该结果，公司秉持审慎原则与保护投资者利益的立场，已暂停在中国的后续入组及相关费用支出，并启动对研发方向的全面复盘。敬请广大投资者注意投资风险!公司将严格按照法规要求及时履行信息披露义务!

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2579464483?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-31 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579464483","market":"fut","top_or_hot":-1,"title":"康芝药业：暂停苏拉明钠临床入组","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300086\">康芝药业</a>(300086)10月30日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘你好，康大和美国合作公司的苏拉明钠治疗肾损伤的临床进展如何了</p><p>康芝药业回复：尊敬的投资者，您好！公司关于苏拉明钠对利尿剂抵抗的急性肾损伤适应症研究，鉴于有临床试验显示苏拉明钠在对利尿剂抵抗的急性肾损伤适应症上未观察到统计学显著获益。基于该结果，公司秉持审慎原则与保护投资者利益的立场，已暂停在中国的后续入组及相关费用支出，并启动对研发方向的全面复盘。敬请广大投资者注意投资风险!公司将严格按照法规要求及时履行信息披露义务!</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康芝药业：暂停苏拉明钠临床入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康芝药业：暂停苏拉明钠临床入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-31 20:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2025103100047038.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，康芝药业(300086)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，康大和美国合作公司的苏拉明钠治疗肾损伤的临床进展如何了康芝药业回复：尊敬的投资者，您好！公司关于苏拉明钠对利尿剂抵抗的急性肾损伤适应症研究，鉴于有临床试验显示苏拉明钠在对利尿剂抵抗的急性肾损伤适应症上未观察到统计学显著获益。基于该结果，公司秉持审慎原则与保护投资者利益的立场，已暂停在中国...</p>\n\n<a href=\"https://stock.stockstar.com/RB2025103100047038.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0042","symbol_name":"基因检测","start_time":0,"source_url":"https://stock.stockstar.com/RB2025103100047038.shtml","article_id":"2579464483","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579464483","pubTimestamp":1761914906,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，康芝药业10月30日在投资者关系平台上答复投资者关心的问题。公司关于苏拉明钠对利尿剂抵抗的急性肾损伤适应症研究，鉴于有临床试验显示苏拉明钠在对利尿剂抵抗的急性肾损伤适应症上未观察到统计学显著获益。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300086":"康芝药业","BK0042":"基因检测","BK0048":"二胎政策","BK0239":"医药制造","BK0070":"员工持股"},"translate_title":"Kangzhi Pharmaceutical: Suspension of clinical enrollment of suramin sodium","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300086":1.5},"content_text":"证券之星消息，康芝药业(300086)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，康大和美国合作公司的苏拉明钠治疗肾损伤的临床进展如何了康芝药业回复：尊敬的投资者，您好！公司关于苏拉明钠对利尿剂抵抗的急性肾损伤适应症研究，鉴于有临床试验显示苏拉明钠在对利尿剂抵抗的急性肾损伤适应症上未观察到统计学显著获益。基于该结果，公司秉持审慎原则与保护投资者利益的立场，已暂停在中国的后续入组及相关费用支出，并启动对研发方向的全面复盘。敬请广大投资者注意投资风险!公司将严格按照法规要求及时履行信息披露义务!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579464483","isCrawlerRequest":true}